53
Participants
Start Date
March 31, 2016
Primary Completion Date
October 31, 2018
Study Completion Date
July 12, 2021
Brentuximab Vedotin
"Phase I:~Cohort K: BV on Day 1: 1.2 mg/kg (cycle 1-3) and 1.8 mg/kg (cycle 4) Cohort K+1: BV on Day 1: 1.8 mg/kg (cycle 1-3) and 1.8 mg/kg (cycle 4) Cohort K-1: BV on Day 1: 0.8 mg/kg (cycle 1-3) and 1.8 mg/kg (cycle 4)~Phase II:~BV on Day 1: at the Maximal Tolerated Dose (MTD) defined at Phase I"
Etoposide
100 mg/m² Days 1-2-3 of Cycles 1-2-3
Carboplatine
max 800mg Day 2 of Cycles 1-2-3
Ifosfamide
5 g/m² Day 2 of Cycles 1-2-3
Clinique Universitaire Saint-Luc, Brussels
CHU Dinant Godinne, Yvoir
Institut d'Hématologie de Basse Normandie - CHU Côte de Nacre, Caen
CHU de Dijon - Hôpital le Bocage, Dijon
IUCT Toulouse, Toulouse
CHU Saint Eloi, Montpellier
CHU De Rennes, Rennes
CHU De Nantes, Nantes
CHU De Nancy - Hôpital Brabois, Vandœuvre-lès-Nancy
CHRU Lille - Hôpital Claude Huriez, Lille
CHU De Strasbourg, Strasbourg
Centre Léon Bérard, Lyon
CHU Lyon Sud, Pierre-Bénite
Hôpital Necker, Paris
APHP - Hôpital Saint Louis, Paris
Centre Henri Becquerel, Rouen
CHU de Poitiers - Hôpital de La Milétrie, Poitiers
APHP-Hôpital Henri Mondor, Créteil
Institut Gustave Roussy, Villejuif
Collaborators (1)
Millennium Pharmaceuticals, Inc.
INDUSTRY
The Lymphoma Academic Research Organisation
OTHER